Compugen (CGEN)

385
-6(-1.66%)
  • Volume:
    20,783
  • Bid/Ask:
    382/384
  • Day's Range:
    385 - 393

CGEN Overview

Prev. Close
392
Day's Range
385-393
Revenue
19.01M
Open
386
52 wk Range
217-1,485
EPS
-0.455
Volume
20,783
Market Cap
333.5M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
176,765
P/E Ratio
-2.13
Beta
2.41
1-Year Change
-71.41%
Shares Outstanding
86,624,643
Next Earnings Date
Feb 23, 2023
What is your sentiment on Compugen?
or
Vote to see community's results!

Compugen News

Compugen Analysis

Compugen Company Profile

Compugen Company Profile

Employees
73
Market
Israel
  • Type:Equity
  • Market:Israel
  • ISIN:IL0010852080
  • S/N:1085208

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralBuySell
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Sell
SummaryStrong SellStrong SellNeutralStrong BuyStrong Sell
  • Currently being valued ~315M counting cash on hand and no debt.
    0
    • Well my prediction came true and my $12 order filled today. Immediately it jumped up and I am up over 3% same day. Hoping this follows through with my prediction that it will be going up from here to $15!
      0
      • So wrong I was. Entire market crashed lol
        0
      • too bad you can't erase comments :)
        0
    • Falling wedge pattern. If it doesn't break out now, will fall back down to $12. Buy it then! Good chance it will sky rocket to $15 or more.
      0
      • any news?
        0
        • with a buy stop above $16, short around $13.50-$14. GL
          1
          • Really hope you didn't short
            0
        • Amazing news to come. The stock is about to fly very high.
          2
          • Looking strong on trend as etf’s are buying up this stock in large amounts
            0